Copyright
©The Author(s) 2022.
World J Gastroenterol. Oct 21, 2022; 28(39): 5735-5749
Published online Oct 21, 2022. doi: 10.3748/wjg.v28.i39.5735
Published online Oct 21, 2022. doi: 10.3748/wjg.v28.i39.5735
Table 4 Prevalence of underlying diseases in patients with (group 1) and without (group 2) elevated liver enzymes
| Group 1 | Group 2 | P value | |
| Hospitalization, d, n ± SD | 9.7 ± 5.9 | 8.7 ± 6.5 | 0.2039 |
| Primary hypertension, n/% | 193/32.0 | 21/25.9 | 0.2638 |
| Heart disease, n/% | 32/5.3 | 6/7.4 | 0.4430 |
| Lung disease, n/% | 19/3.2 | 5/6.2 | 0.1652 |
| Diabetes, n/% | 50/8.3 | 9/11.1 | 0.4015 |
| Obesity, n/% | 14/2.3 | 3/3.7 | 0.4532 |
| Hyperlipidemia, n/% | 31/5.1 | 5/6.2 | 0.6962 |
| Podagra, n/% | 12/2.0 | 0 | 0.2002 |
| Kidney disease, n/% | 16/2.7 | 4/4.9 | 0.2518 |
| Prostate disease, n/% | 9/1.5 | 1/1.2 | 0.8546 |
| Urinary tract disease, n/% | 39/6.5 | 6/7.4 | 0.7487 |
| Thyroiditis and goiter, n/% | 21/3.5 | 4/4.9 | 0.5121 |
| Gastrointestinal disease, n/% | 32/5.3 | 3/3.7 | 0.5387 |
| Liver disease, n/% | 22/3.7 | 2/2.5 | 0.5865 |
| Nervous and mental diseases, n/% | 27/4.5 | 1/1.2 | 0.1666 |
| Cancers, n/% | 17/2.8 | 5/6.2 | 0.1098 |
- Citation: Liakina V, Stundiene I, Milaknyte G, Bytautiene R, Reivytyte R, Puronaite R, Urbanoviciute G, Kazenaite E. Effects of COVID-19 on the liver: The experience of a single center. World J Gastroenterol 2022; 28(39): 5735-5749
- URL: https://www.wjgnet.com/1007-9327/full/v28/i39/5735.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i39.5735